GLYMPSE BIO
Glympse Bio develops a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platform technology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.
GLYMPSE BIO
Industry:
Biotechnology Health Care Life Science Medical Device Nanotechnology
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.glympsebio.com
Total Employee:
11+
Status:
Active
Contact:
617-863-3636
Email Addresses:
[email protected]
Total Funding:
93.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Font Awesome
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Flare Therapeutics
Flare Therapeutics is a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
LunaPBC
LunaPBC is a healthcare company that transforms health data into health breakthroughs.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Temasek Holdings
Temasek Holdings investment in Series B - Glympse Bio
New Leaf Venture Partners
New Leaf Venture Partners investment in Series B - Glympse Bio
LS Polaris Innovation Fund
LS Polaris Innovation Fund investment in Series B - Glympse Bio
CRV
CRV investment in Series B - Glympse Bio
Catalio Capital Management
Catalio Capital Management investment in Series B - Glympse Bio
Gilead Sciences
Gilead Sciences investment in Series B - Glympse Bio
GreatPoint Ventures
GreatPoint Ventures investment in Series B - Glympse Bio
Section 32
Section 32 investment in Series B - Glympse Bio
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Glympse Bio
DNS Capital
DNS Capital investment in Series B - Glympse Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-17 | Glympse Appoints Jonathan Wilde, Ph.D., as Chief Scientific Officer to Advance Biosensor Assay Platform |
Official Site Inspections
http://www.glympsebio.com Semrush global rank: 5.51 M Semrush visits lastest month: 1.55 K
- Host name: 233.151.226.35.bc.googleusercontent.com
- IP address: 35.226.151.233
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Glympse Bio"
Glympse Bio - Crunchbase Company Profile & Funding
Glympse Bio develops a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that …See details»
Glympse Bio Company Profile 2024: Valuation, …
Glympse Bio General Information Description. Operator of a diagnostic platform intended to facilitate noninvasive disease monitoring through bio-marker technology. The company's platform utilizes precisely engineered diagnostic …See details»
Sunbird Bio Merges with Glympse Bio to Accelerate …
Aug 9, 2023 – Combined company will operate as Sunbird Bio and focus on advancing clinical-stage platforms with demonstrated potential to enhance patient care in Alzheimer’s disease, other neurological disorders, and early-stage …See details»
Sunbird Bio snaps up Glympse Bio for protein-based diagnostics
Aug 9, 2023 Glympse Bio, developer of an injectable diagnostic platform, has been acquired by Sunbird Bio, which plans to point the companies’ resources toward a new blood test for …See details»
Glympse Bio Company Profile - Office Locations, Competitors
Glympse Bio has 5 employees at their 1 location and $68.7 m in total funding,. See insights on Glympse Bio including office locations, competitors, revenue, financials, executives, …See details»
Sunbird Bio Merges with Glympse Bio to Accelerate Protein-Based ...
Aug 11, 2023 Sunbird Bio, a biotechnology company developing proprietary protein-based technologies to improve the diagnosis and treatment of neurological disorders and early-stage …See details»
Glympse Bio | Company | Mindmaps
Glympse Bio develops a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology ...See details»
Glympse Bio - VentureRadar
Glympse Bio is pioneering an in vivo sensing technology dedicated to transforming disease monitoring. The company has built a product engine enabling... ... Find out ...See details»
Glympse Bio Announces $46.7 Million Series B Financing - PR …
Jul 15, 2020 For more information, please visit www.glympsebio.com. Media Contact Maggie Beller Russo Partners, LLC [email protected] 646-942-5631. SOURCE Glympse Bio.See details»
Glympse Bio, Inc. Raises $22m Series A Financing - BioSpace
Oct 9, 2018 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Glympse Bio, Inc. announced today that it has raised $22 million in Series A funding.The proceeds of this round will be devoted to …See details»
Faster tracking of treatment responses - MIT News
Feb 2, 2021 Glympse Bio uses synthetic biosensors to gather information on how patients are responding to cancer and other therapies, to help clinicians improve treatment. The MIT startup was spun out of the lab of Professor …See details»
Sunbird Bio Merges with Glympse Bio to Accelerate Development …
Aug 9, 2023 CAMBRIDGE, Mass. & SINGAPORE--(BUSINESS WIRE)--Sunbird Bio, a biotechnology company developing proprietary protein-based technologies to improve …See details»
Glympse Bio names first medical chief, offering a peek at the …
Sep 8, 2021 With its injectable biosensor technology well into the clinical development stage, Glympse Bio has its sights set on revolutionizing the way we diagnose diseases and track their …See details»
Glympse to Present Data from First Application of New Liquid …
Nov 1, 2021 For more information, please visit www.glympsebio.com. Investor Contact Matthew Navarro, J.D. Glympse [email protected] Media Contact Maggie Beller Russo Partners, LLC …See details»
Glympse Bio premieres with $22M series A and plan for in-body …
Oct 9, 2018 Glympse Bio, a startup that builds bioengineered, in vivo sensors for disease, has emerged from stealth with a $22 million series A round. The company hopes to develop a …See details»
Glympse Bio Announces $46.7 Million Series B Financing
Proceeds Support PMA-Enabling Study of Glympse Technology in NASH PatientsCAMBRIDGE, Mass., July 15, 2020 /PRNewswire/ -- Glympse Bio (Glympse), a biotechnology company …See details»
Glympse Bio hopes its test will show whether drugs are actually
Jul 17, 2020 Startup Glympse Bio is hoping its nanoparticle-based biosensors, an alternative to traditional biopsies, can help drug developers test whether their own medicines are actually …See details»
Glympse Bio Announces $46.7 Million Series B Financing
CAMBRIDGE, Mass., July 15, 2020 /PRNewswire/ -- Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an …See details»
First-In-Human Data Supporting the Safety of Glympse Bio's …
CAMBRIDGE, Mass., Nov. 13, 2020 /PRNewswire/ -- Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, today announced …See details»
Glympse Bio clears first-in-human safety study of its injectable ...
Nov 16, 2020 RELATED: Gilead brings in Glympse Bio for a peek into NASH using synthetic biomarkers Elsewhere at the AASLD meeting, Gilead and Novo Nordisk presented new data …See details»